Pesquisa: PT-141 (Bremelanotide)

FDA-approved for female sexual arousal disorder

PT-141 (Bremelanotide) Research Papers & Clinical Studies

PT-141 (Bremelanotide) is a peptide studied for its potential therapeutic effects. FDA-approved for female sexual arousal disorder This page indexes all published research papers, clinical trials, and scientific studies related to PT-141 (Bremelanotide) that are available in the PepsReview research library. Each paper includes metadata such as journal name, publication year, citation count, study type, and a summary of key findings. Where available, we provide direct links to the original publication and DOI references.

Researchers can use this index to quickly locate evidence supporting specific PT-141 (Bremelanotide) applications, compare study designs, and evaluate the strength of clinical evidence. Papers are sorted by relevance and citation count. There are currently 5 research papers indexed for PT-141 (Bremelanotide).

For vendor pricing, user reviews, and a complete peptide profile including mechanism of action, benefits, side effects, and regulatory status, visit the main PT-141 (Bremelanotide) profile page.

PT-141 (Bremelanotide)

PT-141 Palatin

Curr Opin Investig Drugs 2004 440 Research Article

Palatin developed PT-141 (bremelanotide) as a nasal spray for erectile dysfunction and female sexual dysfunction, completing Phase IIb trials with Phase III planned.

An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist

J Sex Med 2006 400 Research Article

Study investigating bremelanotide (PT-141), a melanocortin receptor agonist, for improving subjective sexual response in premenopausal women with sexual arousal disorder.

Bremelanotide: New Drug Approved for Treating Hypoactive Sexual Desire Disorder

Ann Pharmacother 2020 120 Review

Bremelanotide (Vyleesi), a melanocortin 4 receptor agonist, FDA-approved for treating hypoactive sexual desire disorder in women, showing significant desire improvement.

Hypoactive Sexual Desire Disorder in Women: Physiology, Assessment, Diagnosis, and Treatment

J Midwifery Womens Health 2021 100 Research Article

Clinical overview of hypoactive sexual desire disorder (HSDD) in women, covering physiology, assessment, diagnosis, and treatment options including melanocortin agonists.

Bremelanotide for Treatment of Female Hypoactive Sexual Desire

Neurol Int 2022 80 Research Article

Review of bremelanotide for hypoactive sexual desire disorder (HSDD) in women, a condition of persistent deficiency of sexual desire causing significant distress.